EPEvangelos Papanikolaou

Evangelos Papanikolaou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evangelos Papanikolaou has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Ioannis Kalogiannidis

    Third Department of Obstetrics and Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece

    3 shared publications
  • Ioannis Tsakiridis

    Third Department of Obstetrics and Gynecology, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece

    3 shared publications
  • Themistoklis Dagklis

    Third Department of Obstetrics and Gynecology, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece

    3 shared publications
  • Georgios Michos

    Third Department of Obstetrics and Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece

    2 shared publications
  • Stergios Kopatsaris

    Third Department of Obstetrics and Gynaecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece

    2 shared publications
  • Aikaterini Apostolopoulou

    Department of Emergency Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece

    1 shared publication

Latest Publications

  • Open Access

    The Impact of Osteopontin and Galectin-7 on the Preoperative Diagnosis of Ovarian Tumors: A Case–Control Study

    by Foteini Chouliara, Aikaterini Sidera, Ioannis Tsakiridis, Areti Kourti, Georgios Michos, Evangelos Papanikolaou, Themistoklis Dagklis, Apostolos Mamopoulos, Kali Makedou, Ioannis Kalogiannidis

    Background/Objectives: Accurate preoperative discrimination between women with ovarian pathology and healthy controls, as well as between benign and malignant ovarian tumors, remains challenging. This study aimed to evaluate the usefulness of osteopontin and galectin-7 on the diagnosis of ovarian tumors. Methods: This prospective single-center case–control study was conducted at the Third Department of Obstetrics & Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece, between 2018 and 2024. Preoperative serum levels of osteopontin, galectin-7, and established tumor markers (CA-125, CA19-9, CA15-3, CEA, AFP) were analyzed. Biomarker distributions were compared using non-parametric tests. Associations with clinical variables were explored using correlation analyses. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed to assess diagnostic performance. Results: The study population included 116 women: 52 healthy controls, 45 patients with benign ovarian tumors, and 19 patients with malignant ovarian tumors. Serum osteopontin and galectin-7 levels did not differ significantly between control and study group (p = 0.562 and p = 0.138, respectively), nor between benign and malignant tumors (p = 0.784 and p = 0.140, respectively). Osteopontin showed no discriminatory ability (AUC = 0.47), while galectin-7 demonstrated weak discrimination (AUC = 0.63). A combined model yielded modest improvement (AUC = 0.69), remaining below clinically meaningful thresholds. CA-125 was the only biomarker significantly associated with malignancy (OR = 1.03, p = 0.038). Galectin-7 levels were higher in premenopausal women and inversely correlated with age, suggesting demographic rather than malignant influence. Conclusions: Despite strong biological relevance, circulating osteopontin and galectin-7 did not provide meaningful diagnostic discrimination between women with ovarian pathology and healthy controls or between benign and malignant ovarian tumors. CA-125 remained the most informative serum marker in this setting. Future efforts should focus on multi-marker strategies integrated with imaging and clinical assessment.

  • Open Access

    Paving the Way for ERAS in German Gynecologic and Gynecologic Oncology Departments: Insights into Barriers, Facilitators and Practical Strategies

    by Cara Thiel, Helena Schorling, Lina Judit Schiestl, Mona Wanda Schmidt, Anne-Sophie Heimes, Kathrin Stewen, Gilbert Georg Klamminger, Lea Omogbehin, Katharina Delfs, Konstantin Hofmann, et al.

    Background: Enhanced Recovery After Surgery (ERAS) protocols improve postoperative outcomes and promote multidisciplinary, evidence-based perioperative care. However, ERAS adoption in gynecological departments remains inconsistent, and the underlying implementation challenges are poorly understood. Objective: To identify key barriers, facilitators, and preferred implementation strategies influencing ERAS adoption in German gynecological departments, and to assess whether clinicians’ ERAS knowledge or institutional certification shapes these perceptions. Methods: We conducted a nationwide, web-based cross-sectional survey of gynecologic clinicians in Germany. The questionnaire assessed ERAS-related knowledge, current implementation status, and perceived barriers, facilitators, and strategies. Statistical analyses included equality of proportions tests, logistic regression, and internal consistency measurement. Results: A total of 116 clinicians participated; 66 provided data on barriers and 64 on facilitators and strategies. Only 37.9% reported routine ERAS use. The most frequently identified barriers were limited ERAS knowledge (40.9% “very important”) and insufficient personnel resources (40.9%). The strongest facilitators were improved patient well-being, reduced morbidity, and higher patient satisfaction (each >60% “very important”). High-impact implementation strategies included informational materials, workshops, and online training. Well-informed clinicians had significantly higher odds of reporting a positive professional impact of ERAS (OR = 9.0, p = 0.001). Conclusions: ERAS implementation in gynecological settings remains restricted by staff knowledge gaps and personnel limitations. Patient-centered benefits and interactive educational strategies serve as powerful facilitators. Enhanced staff education and multidisciplinary support structures may substantially improve ERAS uptake and contribute to greater professional satisfaction among clinicians.


  • Open Access

    Management of Endometrial Cancer: A Comparative Review of Guidelines

    by Stergios Kopatsaris, Ioannis Tsakiridis, Georgios Kapetanios, Fotios Zachomitros, Georgios Michos, Evangelos Papanikolaou, Apostolos Athanasiadis, Themistoklis Dagklis, Ioannis Kalogiannidis

    Endometrial cancer is the most frequently diagnosed gynecological cancer. The aim of this study was to summarize and compare the most recent guidelines regarding its management. A comparative review of guidelines from the European Society of Gynecological Oncology, the European Society for Radiotherapy and Oncology, the European Society of Pathology, the European Society for Medical Oncology, the Cancer Council of Australia, the British Gynecological Cancer Society, the National Comprehensive Cancer Network, and the American College of Obstetricians and Gynecologists was carried out. The comparison of guidelines highlighted common recommendations and key differences regarding the most basic aspects of endometrial cancer management. Certain differences were identified in the options of surgical procedures based on endometrial biopsy and lymph node infiltration. Minor differences were identified in the management of recurrent disease, while the more pronounced differences were found in the follow-up procedure. The development of consistent international protocols in similar resource settings may lead to a more consistent classification, as well as to common lines regarding surgical approaches, risk stratification and the way patients should be monitored following the remission of endometrial cancer.


  • Open Access

    Accuracy of Frozen Section Biopsy in the Diagnosis of Endometrial Cancer: A Systematic Review and Meta-Analysis

    by Stergios Kopatsaris, Aikaterini Apostolopoulou, Ioannis Tsakiridis, Antigoni Tranidou, Fotios Zachomitros, Evangelos Papanikolaou, Alexandros Daponte, Ioannis Kalogiannidis, Themistoklis Dagklis

    The early and accurate diagnosis of endometrial cancer is of paramount importance for the survival of these patients. The aim of this study was to systematically appraise the available data regarding the accuracy of frozen section biopsy in diagnosing endometrial cancer. A thorough literature search was performed in PubMed/Medline, Scopus and the Cochrane Central Register of Controlled Trials databases from inception up to January 2023, with the use of specific, relevant key terms. A quality evaluation for each study was performed with the QUADAS-2 tool, whereas a bivariate random-effect model was performed to generate a summary receiver-operated curve. Heterogeneity was evaluated with Cochrane Q and Higgins’ I2 statistics. Subgroup analyses were performed for studies focused on atypical hyperplasia and those focused on endometrial cancer. The search yielded 47 studies, involving 7790 patients with endometrial cancer. Among them, only 11 could be included in the quantitative analysis. QUADAS-2 evaluation resulted in rather high quality among the included studies. Quantitative synthesis resulted in a pooled sensitivity of 0.863 and pooled specificity of 0.916. The AUC was 0.948, the Q statistic was 10.488 (10 df, p = 0.399) and Higgins’ I2 (4.655%) reported no significant heterogeneity. Subgroup analyses based on the diagnosis revealed a pooled sensitivity 0.886, specificity 0.862 and AUC 0.934 for endometrial cancer versus a sensitivity of 0.816, specificity of 0.962 and AUC 0.939 for atypical hyperplasia. Frozen section appears as a valid and reliable diagnostic tool for endometrial cancer. Its reliability seems to be even higher for the diagnosis of atypical hyperplasia. Therefore, this method may be considered in clinical practice and in settings with appropriate resources.